Ophthalmic Business News

UBX1325 met safety and efficacy endpoints at 24 weeks in the phase 2 BEHOLD study in patients with diabetic macular edema, according to a press release from Unity Biotechnology.

The NT-501 implant demonstrated positive results in two replicative phase 3 clinical trials for the treatment of macular telangiectasia type 2, according to a press release from Neurotech Pharmaceuticals.

Aurion Biotech has won the Prix Galien Award for Best Startup in Biotech/Pharma, recognizing the company’s clinically validated cell therapy for corneal endothelial dystrophies, according to a press release.

Today’s inflationary environment has thrown a wrench into the wealth creation ability of many asset classes, further underscoring the need for good financial security from your career.

Once-daily dosing of NCX 470 demonstrated noninferiority compared with latanoprost in lowering IOP in patients with open-angle glaucoma or ocular hypertension in the phase 3 Mont Blanc clinical trial.

CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Warren Foust, of Johnson & Johnson Vision, discusses the launch of the Tecnis Symfony OptiBlue IOL and provides an overview of other featured announcements.

CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Ran Yam, of NovaSight, discusses positive topline study data for the CureSight amblyopia therapy device.

CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Yari L. Mitchell, of AcuFocus, provides an update on IOLs for presbyopia correction.

Lenz Therapeutics reported positive topline data from the phase 2 INSIGHT clinical trial investigating LNZ100 and LNZ101 for the treatment of presbyopia.

CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Gustavo De Moraes, MD, PhD, MPH, of Ora, discusses the Ora EyeCup, a new imaging device that monitors eye redness and irritation.